High-Dose Calcitriol, Zoledronate, and Dexamethasone for the Treatment of Progressive Prostate Carcinoma
Academic Article
Overview
MeSH Major
Calcitriol
Carcinoma
Dexamethasone
Diphosphonates
Imidazoles
Prostatic Neoplasms
abstract
Calcitriol was well tolerated at doses up to and including 30 microg 3 times per week in combination with intravenous zoledronate 4 mg monthly, with or without dexamethasone, in patients with progressive prostate carcinoma. Peak plasma levels in the 24 microg and 30 microg cohorts were greater than the levels associated with antitumor effects preclinically. Due to the cumbersome dosing schedule and the lack of significant activity observed, Phase II trials of this regimen are not planned.
